Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07444320

Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System

A Multicenter Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System in Patients With Atrial Fibrillation

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Boston Scientific Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).

Detailed description

The objective of this feasibility study is to: * Evaluate the initial safety and acute performance of investigational waveform(s) delivered using the FARAPULSE™ PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF). * Assess the feasibility of the ablation workflow and waveform delivery. * Characterize acute and chronic lesion durability, procedure efficiency, and waveform exposure patterns.

Conditions

Interventions

TypeNameDescription
DEVICEFARAPULSE™ Pulsed Field Ablation (PFA) SystemThe FARAWAVE™ PFA Catheter will be used to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation. The FARASTAR™ Generator will be used in conjunction with the FARAWAVE™ PFA Catheter to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation. The FARADRIVE™ Steerable Sheath will be used for percutaneous catheter introduction into the chambers of the heart, including the left side of the heart through the interatrial septum.

Timeline

Start date
2026-02-12
Primary completion
2028-02-01
Completion
2028-02-01
First posted
2026-03-02
Last updated
2026-03-31

Locations

2 sites across 2 countries: Croatia, Czechia

Source: ClinicalTrials.gov record NCT07444320. Inclusion in this directory is not an endorsement.